Surveillance Requirements for Fatty Liver Disease
All patients with NAFLD should undergo initial risk stratification using FIB-4 score (or NAFLD Fibrosis Score), with repeat testing every 2-3 years for low-risk patients and more intensive monitoring with elastography for those with intermediate or high scores. 1
Initial Assessment and Baseline Testing
When evaluating a patient with NAFLD, obtain the following baseline laboratory tests:
- Complete metabolic panel (includes ALT, AST, albumin)
- Complete blood count (for platelet count)
- Lipid panel
- Hemoglobin A1c or fasting glucose
- TSH (to exclude hypothyroidism)
These tests allow calculation of simple fibrosis scores and identify metabolic comorbidities that increase risk of disease progression 2, 1.
Screen for alcohol use with validated tools (AUDIT or AUDIT-C) to exclude alcohol-related liver disease 1. Evaluate for other liver diseases including hepatitis B, hepatitis C, autoimmune hepatitis, and hemochromatosis based on clinical context 2.
Two-Tier Fibrosis Assessment Strategy
First Tier: Simple Fibrosis Scores
Calculate FIB-4 score as the primary screening tool using age, AST, ALT, and platelet count 1. This is the most cost-effective and widely validated approach.
FIB-4 interpretation:
- <1.3 (or <2.0 if age >65 years): Low risk for advanced fibrosis - repeat FIB-4 every 2-3 years 1
- 1.3-2.67: Indeterminate risk - proceed to second-tier testing
- >2.67: High risk for advanced fibrosis (60-80% positive predictive value) - proceed to second-tier testing 1
Alternative: NAFLD Fibrosis Score can be used instead of FIB-4, with cutoffs of <-1.455 (low risk) and >0.676 (high risk) 2.
Second Tier: Elastography or Specialty Referral
For patients with FIB-4 >1.3 (or >2.0 if age >65):
- Vibration-controlled transient elastography (VCTE/FibroScan) is the preferred imaging modality, FDA-approved and widely available 2, 3
- Magnetic resonance elastography (MRE) offers highest accuracy but limited by cost and availability 2, 3
- Enhanced Liver Fibrosis (ELF) panel (if available) has 80% sensitivity and 90% specificity for advanced fibrosis 2
Consider hepatology referral for patients with:
- High-risk scores on both simple scores and elastography
- Evidence of advanced fibrosis (F3-F4)
- Uncertainty in diagnosis
- Need for liver biopsy consideration
Surveillance Intervals Based on Fibrosis Stage
Low Risk (FIB-4 <1.3 or <2.0 if >65 years)
- Repeat FIB-4 every 2-3 years 1
- This interval is supported by prospective data showing only 12% of patients with type 2 diabetes had significant liver stiffness progression over 3 years 1
Intermediate Risk (FIB-4 1.3-2.67)
- Proceed to elastography or specialty evaluation
- If elastography excludes advanced fibrosis: annual to biennial monitoring with repeat FIB-4 and/or elastography
- Frequency depends on presence of metabolic risk factors (diabetes, obesity, metabolic syndrome)
High Risk/Advanced Fibrosis (FIB-4 >2.67 or elastography suggesting F3-F4)
- Refer to hepatology for confirmation and cirrhosis surveillance
- If cirrhosis confirmed: HCC surveillance with ultrasound ± AFP every 6 months
- Upper endoscopy for varices screening if cirrhosis present
- More frequent monitoring of fibrosis markers (annually or as directed by specialist)
Key Clinical Pitfalls
Age-related FIB-4 adjustment is critical: The standard cutoff of 1.3 has poor specificity in patients >65 years, leading to excessive false positives. Use the higher cutoff of 2.0 in this population 1.
Patients with multiple metabolic risk factors warrant closer surveillance: Those with type 2 diabetes, hypertension, and obesity have highest risk for adverse outcomes and may progress more rapidly 2.
Normal ALT does not exclude significant disease: Patients can have advanced fibrosis with normal aminotransferases, though elevated ALT increases risk of progression to cirrhosis and HCC 1.
Obesity affects elastography reliability: VCTE has increasing failure rates with higher BMI; MRE is less affected but more expensive 3.